Henry Gómez
A5049679970- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gene expression and cancer classification
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Molecular Biology Techniques and Applications
EsSALUD
2015-2025
The University of Texas MD Anderson Cancer Center
2007-2025
Instituto Nacional de Enfermedades Neoplásicas
2015-2024
Universidad Ricardo Palma
2019-2024
ORCID
2024
Universidad Peruana Cayetano Heredia
2020-2024
Centre Hospitalier Universitaire de Rouen
2023
Consorci Sanitari Garraf
2023
Hospital de Sant Joan Despí Moisès Broggi
2023
International Breast Cancer Study Group
2022
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of in absence low; however, there uncertainty about for most patients, who have midrange score.We performed prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative cancer. Of 9719 eligible patients follow-up information, 6711 (69%) had 11 to 25 were randomly assigned receive...
Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, prospectively conducted study in uniformly treated population provides highest level evidence supporting clinical validity and usefulness biomarker.We performed prospective trial involving women hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary...
Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking 2 (HER2), to aromatase letrozole as first-line treatment (HR) -positive metastatic cancer (MBC).Postmenopausal women with HR-positive MBC were randomly assigned daily (2.5 mg orally) plus lapatinib (1,500 or placebo. The primary end point was progression-free...
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy assessed its predictive accuracy on independent cases.One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed oligonecleotide microarrays fine-needle aspiration specimens. predictors pCR from 82 cases 51 cases.Overall rate 26% in both cohorts....
Abstract Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout natural history hormone-dependent breast cancer and delineate functional roles most commonly detected alterations. Experimental Design: studied a total 249 tumor specimens from 208 patients. The include 134 ER-positive (ER+/HER2−) and, as controls, 115 ER-negative (ER−) tumors. ER+ samples consist 58 primary cancers 76 metastatic samples. All tumors were sequenced...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival two phase III trials of patients with advanced melanoma. The primary objective the current trial was to prospectively explore candidate biomarkers from tumor microenvironment for associations clinical response ipilimumab.
Ovarian failure is a common toxic effect of chemotherapy. Studies the use gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
Abstract Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features lacking. Experimental Design: We analyzed TILs RD clinically and molecularly characterized TNBCs NAC explored therapeutic strategies targeting combinations MEK inhibitors PD-1/PD-L1–targeted immunotherapy mouse...
Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In lacking pCR, NAC selects subpopulation chemotherapy-resistant tumor cells. To understand the molecular underpinnings driving treatment-resistant TNBCs, we performed comprehensive analyses on residual disease 74 clinically defined TNBCs after NAC, including next-generation sequencing (NGS) 20 matched pretreatment biopsies. Combined NGS and...
The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on 21-gene assay to determine the risk recurrence. Whether level clinical recurrence adds prognostic information is not known.
To determine clinical features and patterns of outcome primary testicular diffuse large B-cell lymphomas (DLCL).A retrospective international survey 373 patients with DLCL.Most presented localized disease (stage I to II), the median age at diagnosis was 66 years (range, 19 91 years). Anthracycline-based chemotherapy administered 255 (68%), prophylactic intrathecal given 68 (18%); 133 (36%) received scrotal radiotherapy. Median overall survival 4.8 years, progression-free 4 years. The curves...
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy lapatinib in HER-2–negative HER-2–uncharacterized MBC. Patients Methods Women with MBC were randomly assigned to first-line therapy paclitaxel 175 mg/m every 3 weeks plus 1,500 mg/d placebo. A preplanned retrospective evaluation HER-2...
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of inhibitor capivasertib, as an addition to fulvestrant therapy, patients with hormone receptor-positive advanced breast cancer are limited.
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer.Patients ErbB2-amplified, cancer previously untreated setting were randomly assigned to one dose cohorts received either 1,500 mg once daily 500 twice daily. Clinical response was at weeks 8 12 every thereafter.A total 138 patients treated for a median 17.6 weeks. The overall rate (complete...
Abstract Introduction Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we identified TNBC subtype that has luminal phenotype and expresses the androgen receptor (AR+). cells derived from these AR + tumors have high frequency phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. The purpose this study was determine if targeting phosphoinositide...
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing mutations. Herein, we measured apoptotic rates cell lines sharing driver oncogene following treatment corresponding inhibitor. There was range inhibitor-induced apoptosis despite comparable inhibition target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels BH3-only pro-apoptotic BIM...
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin (AC) in a trial early breast cancer. However, activity of TC relative AC regimens with taxane (TaxAC) is unknown. Methods In series three adjuvant trials, women were randomly assigned for six cycles (TC6) or standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 docetaxel, doxorubicin, (TAC6). National Surgical Adjuvant Breast Bowel Project (NSABP) B-46-I/USOR 07132 TC6, TAC6, plus bevacizumab. NSABP...